Prescriber Checkup | VANISHPOINT

Prescriber Checkup

The Doctors and Drugs in Medicare Part D

Prescriber Checkup » VANISHPOINT

VANISHPOINT

SYRINGE AND NEEDLE,INSULIN,1ML

At a Glance: This Drug in 2016

2,170
Medicare Part D Claims

Rank: 1865 of 3393

$141K
Retail Cost

Rank: 2374 of 3393

479
Patients

Rank: 1994 of 3393

265
Prescribers

Rank: 2198 of 3393

This Drug's History

Claims

The number of Medicare prescriptions for this drug each year

1,231

2012

2,204

2013

2,357

2014

1,879

2015

2,170

2016

Spending

The total Part D spending on this drug
each year

$77.4K

2012

$147K

2013

$166K

2014

$124K

2015

$141K

2016

Average Patient Cost

Average amount that patients paid each year.

$277

2012

$238

2013

$262

2014

$301

2015

$295

2016

Use by state

State Patients Claims Cost
Pennsylvania 126 667 $43K
Texas 98 413 $24.1K
Oregon 44 339 $23.6K
Massachusetts 41 166 $11.5K
New York 43 125 $8,325
Missouri 31 116 $7,004
Maryland 22 75 $4,922
Minnesota 13 53 $3,596
California 13 43 $3,876
New Mexico 39 $2,272
Virginia 33 $2,392
Florida 23 $900
South Carolina 11 $775
Nebraska 11 $794
North Carolina 11 $752
About This Data

Prescribing data from Medicare’s prescription drug benefit, known as Part D, was compiled and released by the Centers for Medicare and Medicaid Services, the federal agency that oversees the program. The data for 2016 includes more than 1.5 billion prescriptions written by 1.1 million doctors, nurses and other providers. This database lists over 460,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. More than three-fourths of these prescriptions went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to [email protected] and we will update your information. If you have other questions about this data, send a note to [email protected].